Douglas Reznick

机构：Rocky Mountain Cancer Centers

发表论文 5 篇 · 总被引 283 次 · h-index 5

代表论文

• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (2024 · Journal of Clinical Oncology · 被引 126)
• EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors. (2022 · Journal of Clinical Oncology · 被引 16)
• Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer (2006 · Journal of Clinical Oncology · 被引 8)
• Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. (2024 · Journal of Clinical Oncology · 被引 7)